Effects of Aromatase Inhibitors on Heart and Brain Health in Breast Cancer Survivors
Official title: Beyond Cardiotoxicity: Characterizing the Long-term Cardiovascular Side Effects of Breast Cancer Endocrine Treatment
Run by University of Toronto · NCT06776458 · Data updated 2026-11-12
This study looks at how taking aromatase inhibitors affects heart and brain health over time in post-menopausal women who have survived hormone receptor-positive breast cancer.
Quick facts
| Study type | Observational |
|---|---|
| Sex | Women only |
| Enrollment | 112 (estimated) |
| Sponsor | University of Toronto Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | February 1, 2025 |
| Main results expected | September 30, 2026 |
| Study ends | September 30, 2026 |
| Registry record updated | January 15, 2025 |
| Trial ID | NCT06776458 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include post-menopausal women with hormone receptor-positive breast cancer who have received aromatase inhibitor therapy.
✕Probably not a fit
Patients who have previously undergone treatment with tamoxifen or those with other significant cardiovascular conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the long-term cardiovascular and brain health outcomes associated with aromatase inhibitor therapy in post-menopausal women diagnosed with hormone receptor-positive breast cancer. It will compare health indices related to cardiovascular disease in breast cancer survivors at 1, 5, and 10 years post-diagnosis to a control group. The primary focus is on assessing early risk indicators for cardiovascular disease, including aortic stiffness, to better understand the implications of prolonged aromatase inhibitor use.
Why it matters
Potential benefit: If successful, this study could provide critical insights into the cardiovascular risks associated with aromatase inhibitors, potentially leading to improved management strategies for breast cancer survivors.
How similar studies have gone: While studies have indicated cardiovascular risks associated with aromatase inhibitors, this specific long-term observational approach is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Case group: * Biologically female * Post-menopausal with natural (no bilateral oophorectomy) amenorrhea for at least 1 year * If using hormone replacement therapy, limit of a maximum of 3 years of treatment but not within the last 6 months. * Diagnosis of stage I, II, or III breast cancer * Hormone receptor positive breast cancer * HER negative (ER+/PR+/HER-) breast cancer * Breast cancer patients \~1 post-diagnosis who have received aromatase inhibitor therapy * Breast cancer patients \~5 and \~10 years post-diagnosis who have received aromatase inhibitor therapy for at least 2 years * Received surgery/radiation therapies Control group: * Biologically female * Post-menopausal with natural (no bilateral oophorectomy) amenorrhea for at least 1 year * If using hormone replacement therapy, limit of a maximum of 3 years of treatment but not within the last 6 months. Exclusion Criteria: * Previous treatment using tamoxifen endocrine therapy in a pre-or peri-menopausal setting * Major signs or symptoms of cardiovascular diseases, diabetes, or renal disease (taken from the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription 11th edition Table 2.1: pain or discomfort in the chest, neck, jaw, arms with rest or exercise, shortness of breath at rest or with mild exertion, dizziness or syncope, loss of balance or passing out, ankle edema, palpitations or tachycardia, intermittent claudication, known heart murmur, unusual fatigue with usual activities.) * American Heart Association's absolute or relative contraindications for symptom-limited maximal exercise testing (myocardial infarction, aortic or coronary artery stenosis, heart failure, pulmonary embolism or deep vein thrombosis, inflammation of the heart (myocarditis, pericarditis, and/or endocarditis), uncontrolled cardiac arrythmia, advanced or complete electrical heart block, stroke or transient ischemia attack, blood pressure \>200mmHg/100mmHg, a cancer diagnosis other than skin cancer) * Unable to provide informed consent or communicate in English * Mobility limitations to exercise testing (i.e., wheelchair, walker use, limp impeding walking) * Extreme claustrophobia
Where it's running
-
University of Toronto
Toronto, Ontario, Canada Recruiting
Study contacts
- Study coordinator: Amy A. Kirkham, PhD
- Email: amy.kirkham@utoronto.ca
- Phone: 416-946-4069
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Optimal timing of antibody drug conjugate therapy for advanced HER2-negative breast cancer
This trial tests whether giving an antibody drug conjugate before chemotherapy is better or worse than the opposite sequence in women with advanced HER2-negative breast cancer who have progressed after first-line therapy.
-
Auricular Laser Acupuncture for Sleep in Breast Cancer Patients
This trial tests whether active auricular laser acupuncture can improve sleep in women with breast cancer and insomnia compared with a sham laser.
-
Educational video series for women in breast cancer treatment
This study tests whether access to an online sexual health video series helps women with newly diagnosed breast cancer communicate with their providers and access sexual-health services compared to usual care.
-
Auricular Acupressure for Perioperative Anxiety and Pain in Breast Cancer Surgery
This randomized, single‑center trial tests whether NADA ear acupressure can reduce anxiety and pain around surgery for women with newly diagnosed breast cancer.
-
Dextrose injections to loosen chest wall and armpit tightness after breast cancer
This will try ultrasound-guided dextrose injections to relieve persistent chest wall and armpit tightness and improve arm function in women who had breast cancer and did not improve with physical therapy.
-
Vitamin K, d‑chiro‑inositol and α‑lactalbumin for protecting bones during breast cancer hormone therapy
This will test whether adding vitamin K, d‑chiro‑inositol and α‑lactalbumin to calcium and vitamin D better protects bone health in women on hormone therapy for breast cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.